Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Patients on Tirzepitide typically lose between 20- 30% of their body weight within 3-6 months
The first step is taking your comprehensive health assessment which includes a detailed look at your lab work results, BMI calculation, cognitive health evaluation, and a 30-minuts consultation with a clinician
Wegovy should only be used under the guidance of a registered healthcare professional
In a clinical trial, participants with obesity (without diabetes) experienced an average weight loss of 20% with tirzepatide, compared to 13.7% with semaglutide after 72 weeks
The study supports further clinical adoption of this combination therapy and suggests that it could enhance long-term patient outcomes in CHB management
Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2
